- Home
- NAVI vs IRON Comparison
NAVI vs IRON Comparison
Compare NAVI & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAVI
- IRON
- Stock Information
- Founded
- NAVI 1973
- IRON 2017
- Country
- NAVI United States
- IRON United States
- Employees
- NAVI N/A
- IRON N/A
- Industry
- NAVI Investment Bankers/Brokers/Service
- IRON Biotechnology: Pharmaceutical Preparations
- Sector
- NAVI Finance
- IRON Health Care
- Exchange
- NAVI Nasdaq
- IRON Nasdaq
- Market Cap
- NAVI 1.7B
- IRON 1.4B
- IPO Year
- NAVI N/A
- IRON N/A
- Fundamental
- Price
- NAVI $14.74
- IRON $64.29
- Analyst Decision
- NAVI Sell
- IRON Strong Buy
- Analyst Count
- NAVI 8
- IRON 10
- Target Price
- NAVI $14.63
- IRON $73.70
- AVG Volume (30 Days)
- NAVI 898.7K
- IRON 253.9K
- Earning Date
- NAVI 01-29-2025
- IRON 11-12-2024
- Dividend Yield
- NAVI 4.40%
- IRON N/A
- EPS Growth
- NAVI N/A
- IRON N/A
- EPS
- NAVI 0.70
- IRON N/A
- Revenue
- NAVI $1,036,000,000.00
- IRON N/A
- Revenue This Year
- NAVI N/A
- IRON N/A
- Revenue Next Year
- NAVI $1.01
- IRON N/A
- P/E Ratio
- NAVI $20.86
- IRON N/A
- Revenue Growth
- NAVI N/A
- IRON N/A
- 52 Week Low
- NAVI $13.71
- IRON $25.60
- 52 Week High
- NAVI $19.44
- IRON $77.60
- Technical
- Relative Strength Index (RSI)
- NAVI 43.14
- IRON 53.08
- Support Level
- NAVI $14.52
- IRON $62.31
- Resistance Level
- NAVI $15.26
- IRON $67.87
- Average True Range (ATR)
- NAVI 0.35
- IRON 3.04
- MACD
- NAVI -0.06
- IRON -0.46
- Stochastic Oscillator
- NAVI 12.74
- IRON 38.78
About NAVI Navient Corporation
Navient Corp provides technology-enabled education finance and business processing solutions that simplify complex programs and help millions of people achieve success. It operates business in three segments: Federal Education Loans, Consumer Lending and Business Processing.
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company that is dedicated to transforming the lives of patients with hematologic disorders. The company is building a portfolio of inventive therapeutic candidates that affect fundamental pathways of red blood cell biology. Disc Medicine is committed to developing treatments that empower and bring hope to the many patients who suffer from hematologic disease. The Company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis.